Compugen Ltd. (CGEN)
TASE 
NASDAQ (CM) Primary TASE Summary
CGEN Chart
People also search for
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
Compugen Q1 Earnings Call Highlights
Compugen NASDAQ: CGEN said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs.
Compugen Ltd. (CGEN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Compugen Ltd. ever had a stock split?
Compugen Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Eran Ophir CEO | TASE Exchange | IL0010852080 ISIN |
| IL Country | 75 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Compugen Ltd. operates as a clinical-stage therapeutic discovery and development company, based in Holon, Israel, with active research and development efforts across Israel, the United States, and Europe. Specializing in the field of immuno-oncology, Compugen focuses on the research, development, and commercialization of novel therapeutic and product candidates. Leveraging cutting-edge technologies, the company dedicates its efforts to addressing various cancers through a range of promising therapeutic antibodies. Compugen has established multiple collaboration agreements with leading pharmaceutical companies and research institutions including Bayer Pharma AG, Bristol-Myers Squibb, and Johns Hopkins School of Medicine, highlighting its significant role in advancing immuno-oncology therapeutics towards commercialization. Founded in 1993, Compugen stands at the forefront of immunotherapy research aiming to bring innovative treatments to patients worldwide.
Products and Services
COM701: An anti-PVRIG antibody, currently in Phase I clinical study for treating solid tumors. COM701 aims to modulate the immune system response against tumor cells, marking a significant step in immuno-oncology.
COM902: A therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study. Focused on advanced malignancies, COM902 is tested through sequential dose escalations seeking to enhance immune cell activity against cancers.
Bapotulimab: Targets ILDR2 and is in Phase I clinical study for patients with naïve head and neck squamous cell carcinoma. This therapeutic antibody is another innovative approach to stimulate the immune system's ability to fight cancer.
Rilvegostomig: A novel anti-TIGIT/PD-1 bispecific antibody in Phase II clinical study, targeting patients with advanced or metastatic non-small cell lung cancer. Rilvegostomig represents a dual-focused immuno-oncology strategy, blocking two critical immune-inhibitory pathways.
Early-stage Immuno-oncology Programs: Include a range of projects focused to address various mechanisms of immune resistance. These programs are designed to explore newer therapeutics that could overcome challenges faced by current treatments.
COM503: An antibody that blocks the interaction between IL-18 binding protein and IL-18, signifying a high affinity antibody approach to modulate immune responses against cancerous cells.
